Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2018.
Commission
File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation
of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ]
Form 40-F [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ___
Note: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ___
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home
country exchange on which the registrant's securities are traded,
as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant's
security holders, and, if discussing a material event, has already
been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
This
Report of Foreign Private Issuer on Form 6-K and the attached
exhibit 99.1 shall be incorporated by reference into the Company's
effective Registration Statements on Form F-3, as amended and
supplemented (Registration Statement Nos. 333-172796 and
333-218297), filed with the Securities and Exchange Commission,
from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished
by Intellipharmaceutics International Inc. under the Securities Act
of 1933 or the Securities Exchange Act of 1934.
On
August 15, 2018, Intellipharmaceutics International Inc. (the
"Company") held special meeting of shareholders (the "Meeting"). At
the Meeting, shareholders of the Company approved a special
resolution granting our Board of Directors discretionary authority
to implement a consolidation of the issued and outstanding common
shares of the Company on the basis of a consolidation ratio to be
selected by the directors of the Company within a range between
five (5) pre-consolidation common shares for one (1)
post-consolidation common share and 15 pre-consolidation common
shares for one (1) post-consolidation common share, all as more
particularly described in the Management Information Circular of
the Company dated July 6, 2018 included as Exhibit 99.2 to the
Company’s report on Form 6-K furnished to the U.S. Securities
and Exchange Commission on July 13, 2018 (a "reverse split"). A
copy of the report of voting results is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
No
decision has been made yet by the Board of Directors of the Company
to implement a reverse split.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics International Inc.
(Registrant)
/s/
Dr. Amina Odidi
|
|
Date: August 15,
2018
|
Dr. Amina Odidi
President and Chief Operating Officer
|
EXHIBIT LIST
|
Exhibit
|
Description
|
|
99.1
|
Report of Voting Results
|